Inspire Medical Systems, Inc. (INSP) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Balance Sheet ⢠Margin Compression ⢠SBC Burden INSP has a fortress-like balance sheet and healthy gross margins, but recent quarterly profitability and cash flow weakened sharply as operating expenses and stock-based compensation overwhelmed gross profit.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Weak Rally Fails ⢠Breakdown Risk Support Level: $40.00â$40.50 Resistance Level: $42.20â$44.70 INSP remains in a short-term downtrend over the last month, but support around $40.00â$40.50 is still holding; a break below $40.05 would point to more downside, while $42.20â$44.70 is the near-term resistance zone.
Sentiment & News
Key News Insights: ⢠Post-earnings selloff ⢠Conference transcript ⢠Next-steps focus INSP is facing a sharp post-earnings selloff, with investors now focused on what management says next and whether recent results can stabilize sentiment.
AI Summary
INSP has shifted from a clean growth compounder to a proof-needed recovery story: despite strong gross margins and a fortress balance sheet, the stock likely needs clear procedure-volume reacceleration and operating leverage improvement before upside is credible, or else execution risk and dilution pressure will keep capping the multiple.
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |